Kevin J. Rodriguez-Cruz earned his B.S. in Microbiology from the University of Puerto Rico in Arecibo and later completed his B.S. in Pharmacy Studies and Pharm.D. at Samford University McWhorter School of Pharmacy. During his pharmacy studies, he focused on cystic fibrosis research, specifically investigating how Lumacaftor affects the function of the F508del cystic fibrosis transmembrane conductance regulator. Currently, as a T32 post-doctoral fellow in translational pharmacogenomics under Dr. Limdi, Kevin is engaged in multiple projects, including the Phase IV eMERGE study, where he evaluates genomic risk scores for breast cancer and cardiovascular disease. He also co-leads a project on CYP2C19-guided antiplatelet therapy in ischemic stroke, conducting both retrospective and prospective studies to understand the role of genetic variation in treatment outcomes. Kevin's research aims to advance personalized medicine by integrating genomic data into clinical practice.